Microsatellite Instability as a Prognostic Factor in Resected Colorectal Cancer Liver Metastases
- Riad Haddad MD,
- Robert T. Ogilvie MD, FRCPC,
- Marina Croitoru BSc,
- Victoria Muniz MD,
- Robert Gryfe MD, PhD, FRCSC,
- Aaron Pollet MD,
- Preshanthini Shanmugathasan BSc,
- Timothy Fitzgerald MD, FRCSC,
- Calvin H. L. Law MD, MPH, FRCSC,
- Sherif S. Hanna MD, FRCSC, FACS,
- Serge Jothy MD, PhD, FRCPC,
- Mark Redston MD, FRCPC,
- Steven Gallinger MD, MSc, FRCSC,
- Andrew J. Smith MD, MSc, FRCSC, FACS
- … show all 14 hide
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Background: Two distinct genetic mutational pathways characterized by either chromosomal instability or high-frequency microsatellite instability (MSI-H) are currently recognized in the pathogenesis of colorectal cancer (CRC). Recently, it has been shown that patients with primary CRC that displays MSI-H have a significant, stage-independent, multivariate survival advantage. Untreated CRC hepatic metastases are incurable and are associated with a median survival of 4 to 12 months. Conversely, surgical resection in selected patients results in a 20% to 50% cure rate. The aim of this study was to investigate the prognostic importance of MSI-H in patients undergoing resection of hepatic CRC metastases.
Methods: DNA was extracted from paraffin-embedded, resected metastatic CRC liver lesions and corresponding normal liver parenchyma from 190 patients. MSI-H status was determined by polymerase chain reaction–based evaluation of the noncoding mononucleotide repeats BAT-25 and BAT-26.
Results: MSI was detected in tumors from 5 (2.7%) of the 190 CRC patients. All MSI-H tumors were in patients with node-positive CRC primary tumors. The median survival after hepatic resection of MSI-H and non–MSI-H tumors was 67 and 61 months, respectively (P = .9).
Conclusions: These data suggest that MSI-H is not a common feature in resected CRC liver metastases and do not suggest a role for MSI in stratifying good versus poor prognosis in these patients.
- Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature 1998; 396: 643–9. CrossRef
- Gryfe R, Kim H, Hsieh ET, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med 2000; 342: 69–77. CrossRef
- Cunningham JM, Kim CY, Christensen ER, et al. The frequency of hereditary defective mismatch repair in a prospective series of unselected colorectal carcinomas. Am J Hum Genet 2001; 69: 780–90. CrossRef
- Redston M. Carcinogenesis in the GI tract: from morphology to genetics and back again. Mod Pathol 2001; 14: 236–45.
- Fong Y, Fortner J, Sun RL, et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309–18. CrossRef
- Fong Y, Cohen AM, Fortner JG, et al. Liver resection for colorectal metastases. J Clin Oncol 1997; 15: 938–46.
- Altendorf-Hofmann A, Scheele J. A critical review of the major indicators of prognosis after resection of hepatic metastases from colorectal carcinoma. Surg Oncol Clin North Am 2003; 12: 165–92, xi.
- Boland CR, Thibodeau SN, Hamilton SR, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res 1998; 58: 5248–57.
- Zhou XP, Hoang JM, Li YJ, et al. Determination of the replication error phenotype in human tumors without the requirement for matching normal DNA by analysis of mononucleotide repeat microsatellites. Genes Chromosomes Cancer 1998; 21: 101–7. CrossRef
- Zhou XP, Hoang JM, Cottu P, et al. Allelic profiles of mononucleotide repeat microsatellites in control individuals and in colorectal tumors with and without replication errors. Oncogene 1997; 15: 1713–8.
- Loukola A, Eklin K, Laiho P, et al. Microsatellite marker analysis in screening for hereditary nonpolyposis colorectal cancer (HNPCC). Cancer Res 2001; 61: 4545–9.
- Marcus VA, Madlensky L, Gryfe R, et al. Immunohistochemistry for hMLH1 and hMSH2: a practical test for DNA mismatch repair-deficient tumors. Am J Surg Pathol 1999; 23: 1248–55. CrossRef
- Smith DL, Soria JC, Morat L, et al. Human telomerase reverse transcriptase (hTERT) and Ki-67 are better predictors of survival than established clinical indicators in patients undergoing curative hepatic resection for colorectal metastases. Ann Surg Oncol 2004; 11: 45–51.
- Ribic CM, Sargent DJ, Moore MJ, et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349: 247–57. CrossRef
- Hemminki A, Mecklin JP, Jarvinen H, et al. Microsatellite instability is a favorable prognostic indicator in patients with colorectal cancer receiving chemotherapy. Gastroenterology 2000; 119: 921–8.
- Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med 2003; 348: 919–32. CrossRef
- Kochhar R, Halling KC, McDonnell S, et al. Allelic imbalance and microsatellite instability in resected Duke’s D colorectal cancer. Diagn Mol Pathol 1997; 6: 78–84.
- Schneider A, Rohr S, Kelly MD, et al. Microsatellite instability and allelic imbalance in primary and secondary colorectal cancer. Aust N Z J Surg 2000; 70: 587–92.
- Rosty C, Chazal M, Etienne MC, et al. Determination of microsatellite instability, p53 and K-RAS mutations in hepatic metastases from paients with colorectal cancer: relationship with response to 5-fluorouracil and survival. Int J Cancer 2001; 95: 162–7.
- Chen WS, Chen JY, Liu JM, et al. Microsatellite instability in sporadic-colon-cancer patients with and without liver metastases. Int J Cancer 1997; 74: 470–4.
- Ishimaru G, Adachi J, Shiseki M, et al. Microsatellite instability in primary and metastatic colorectal cancers. Int J Cancer 1995; 64: 153–7.
- Weber JC, Nakano H, Bachellier P, et al. Is a proliferation index of cancer cells a reliable prognostic factor after hepatectomy in patients with colorectal liver metastases? Am J Surg 2001; 182: 81–8.
- Costa A, Doci R, Mochen C, et al. Cell proliferation-related markers in colorectal liver metastases: correlation with patient prognosis. J Clin Oncol 1997; 15: 2008–14.
- Lind DS, Parker GA, Horsley JS III, et al. Formal hepatic resection of colorectal liver metastases. Ploidy and prognosis. Ann Surg 1992; 215: 677–83.
- De Jong KP, Stellema R, Karrenbeld A, et al. Clinical relevance of transforming growth factor alpha, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors. Hepatology 1998; 28: 971–9.
- Saw RP, Koorey D, Painter D, et al. p53, DCC and thymidylate synthase as predictors of survival after resection of hepatic metastases from colorectal cancer. Br J Surg 2002; 89: 1409–15.
- Crowe PJ, Yang JL, Berney CR, et al. Genetic markers of survival and liver recurrence after resection of liver metastases from colorectal cancer. World J Surg 2001; 25: 996–1001.
- Microsatellite Instability as a Prognostic Factor in Resected Colorectal Cancer Liver Metastases
Annals of Surgical Oncology
Volume 11, Issue 11 , pp 977-982
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Microsatellite instability
- Colorectal cancer
- Hepatic metastases
- Molecular markers
- Industry Sectors
- Riad Haddad MD (1) (2)
- Robert T. Ogilvie MD, FRCPC (3) (4)
- Marina Croitoru BSc (1)
- Victoria Muniz MD (1)
- Robert Gryfe MD, PhD, FRCSC (1) (2)
- Aaron Pollet MD (2) (4)
- Preshanthini Shanmugathasan BSc (3)
- Timothy Fitzgerald MD, FRCSC (2) (3)
- Calvin H. L. Law MD, MPH, FRCSC (2) (3)
- Sherif S. Hanna MD, FRCSC, FACS (2) (3)
- Serge Jothy MD, PhD, FRCPC (3)
- Mark Redston MD, FRCPC (2) (4)
- Steven Gallinger MD, MSc, FRCSC (1) (2)
- Andrew J. Smith MD, MSc, FRCSC, FACS (2) (3) (5)
- Author Affiliations
- 1. Centre for Cancer Genetics, Samuel Lunenfeld Research Institute, Toronto, Ontario, Canada
- 2. University of Toronto, Toronto, Ontario, Canada
- 3. Sunnybrook and Women’s Health Sciences Centre, Toronto, Ontario, Canada
- 4. Laboratory Medicine and Pathobiology, Mount Sinai Hospital, Toronto, Ontario, Canada
- 5. Sunnybrook and Women’s Health Sciences Centre, T-Wing, Room T2-057, 2075 Bayview Ave., Toronto, Ontario, Canada, M4N 3M5